Arrowstreet Capital
JNCE

Arrowstreet Capital’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Arrowstreet Capital’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,728
Closed -$96K – 2628
2020
Q4 		$96K Sell
13,728
-27,251
-66% -$212K ﹤0.01% 2225
2020
Q3 		$334K Buy
+40,979
New +$254K ﹤0.01% 2121
2020
Q1 		– Sell
-26,828
Closed -$234K – 2193
2019
Q4 		$234K Buy
+26,828
New +$145K ﹤0.01% 1604

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Arrowstreet Capital's JNCE Position: Q1 2021 in Review

Arrowstreet Capital sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2021, closing a stake of 13,728 shares — an estimated $96K sold.

Arrowstreet Capital first reported a position in JNCE in Q4 2019 and held it in 3 quarters. The position peaked at $334K in Q3 2020. 124 funds tracked by Wall St. Rank hold JNCE as of Q1 2021.

  • Arrowstreet Capital reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 13,728 Jounce Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $96K.
  • Arrowstreet Capital first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • Arrowstreet Capital's Jounce Therapeutics, Inc. Common Stock position peaked at $334K in Q3 2020.
  • 124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.